Javlor
(vinflunine)Phase 3Small molecule
Bristol-Myers SquibbVinflunine is used to treat advanced bladder cancer in patients who have already received other chemotherapy treatments. It works by stopping cancer cells from dividing and growing.[1] Javlor is currently being investigated across 15 indications[3], with its most advanced program in Phase 3.[1]
Javlor is one of 310 small molecule programs targeting Head and Neck Carcinoma. It is currently in Phase 3.
15
Indications
26
Total Trials
2
Active Trials
309
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 15 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Javlor
Bristol-Myers SquibbPhase 3
Tecentriq
RochePreclinical
Avastin
BBio-Thera Solutions
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Bladder Cancer5 trials
Breast Cancer4 trials
Transitional Cell Carcinoma3 trials
Urothelial Cancer2 trials
10 more indications
Advanced Urothelial Cancer1 trial
Non-Small Cell Lung Cancer1 trial
Head and Neck Cancer1 trial
Chemotherapy1 trial
Metastatic Solid Tumors1 trial
Advanced Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for vinflunine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Tubulin Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company